Chang K. et al. (1996) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. PNAS. 93(1): 136-140.
Liu X. et al. (2020) Multiple proteases are involved in mesothelin shedding by cancer cells. Commun Biol. 3: 728.
Mesothelin (MSLN) is also known as CAK1 antigen, Pre-pro-megakaryocyte potentiating factor, which belongs to the mesothelin family. Mesothelin/MSLN can be proteolytically cleaved into the following two chains by a furin-like convertase: Megakaryocyte-potentiating factor (MPF) and the cleaved form of mesothelin. Both MPF and the cleaved form of mesothelin are N-glycosylated. Mesothelin/MSLN can interacts with MUC16. The membrane-anchored form of MSLN may play a role in cellular adhesion. MPF potentiates megakaryocyte colony formation in vitro. Mesothelin (MSLN) is a lineage restricted cell surface protein expressed in about 30% of human cancers and high MSLN expression is associated with poor survival in several different cancers. The restricted expression of MSLN in normal tissue and its frequent expression in cancers make MSLN an excellent target for antibody-based therapies.
1μg (R: reducing condition, N: non-reducing condition).
The purity of MSLN His Tag Protein, Cynomolgus is more than 95% determined by SEC-HPLC.
Immobilized MSLN His Tag Protein, Cynomolgus (Cat. No. UA011056) at 2.0μg/mL (100μL/well) can bind Anti-Human MSLN Monoclonal Antibody (Amatuximab) with EC50 of 2.67-4.78ng/mL.
您现在的位置：